Clinical trials
Phase 2 Nasopharyngeal Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Dana-Farber Cancer Institute | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| University of Chicago | 2 |
| Alliance for Clinical Trials in Oncology | 1 |
| Assuntina Sacco, M.D. | 1 |
| Burzynski Research Institute | 1 |
| Celgene | 1 |
| Eastern Cooperative Oncology Group | 1 |
| Fox Chase Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nasopharyngeal Neoplasms | 24 |
| Head and Neck Neoplasms | 15 |
| Hypopharyngeal Neoplasms | 10 |
| Mouth Neoplasms | 10 |
| Oropharyngeal Neoplasms | 10 |
| Laryngeal Neoplasms | 9 |
| Nasopharyngeal Carcinoma | 5 |
| Salivary Gland Neoplasms | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.